Published in Front Immunol on September 06, 2017
Complement. First of two parts. N Engl J Med (2001) 11.16
Complement: a key system for immune surveillance and homeostasis. Nat Immunol (2010) 10.37
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med (2006) 6.90
New approaches to the treatment of dense deposit disease. J Am Soc Nephrol (2007) 3.02
Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol (2012) 2.62
Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest (2000) 2.45
Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology (N Y) (1995) 2.45
Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol (2009) 2.06
Hereditary angio-oedema. Lancet (2012) 1.95
Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. J Immunol (2003) 1.89
Treatment of experimental arthritis by targeting synovial endothelium with a neutralizing recombinant antibody to C5. Arthritis Rheum (2012) 1.61
Mannan-binding lectin recognizes structures on ischaemic reperfused mouse kidneys and is implicated in tissue injury. Scand J Immunol (2005) 1.44
Collectin-11 detects stress-induced L-fucose pattern to trigger renal epithelial injury. J Clin Invest (2016) 1.43
New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. Immunobiology (2012) 1.39
The mannose-binding lectin-pathway is involved in complement activation in the course of renal ischemia-reperfusion injury. Am J Pathol (2004) 1.28
Overview of complement activation and regulation. Semin Nephrol (2013) 1.26
Medullary plasma flow and intravascular leukocyte accumulation in acute renal failure. Kidney Int (1974) 1.21
Progress and Trends in Complement Therapeutics. Adv Exp Med Biol (2013) 1.20
FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Oncologist (2008) 1.17
The complement system in ischemia-reperfusion injuries. Immunobiology (2012) 1.10
Therapeutic strategy with a membrane-localizing complement regulator to increase the number of usable donor organs after prolonged cold storage. J Am Soc Nephrol (2006) 1.08
Solution structures and integrin binding activities of an RGD peptide with two isomers. Biochemistry (2001) 1.07
Complement fragments C3a and C5a: the salt and pepper of the immune response. Eur J Immunol (2010) 1.07
Ischaemia-reperfusion injury: a major protagonist in kidney transplantation. Nephrol Dial Transplant (2013) 1.01
The use of eculizumab in renal transplantation. Clin Transplant (2013) 1.00
Complement in disease: a defence system turning offensive. Nat Rev Nephrol (2016) 0.97
Selective therapeutic control of C5a and the terminal complement complex by anti-C5 single-chain Fv in an experimental model of antigen-induced arthritis in rats. Arthritis Rheum (2007) 0.97
Mannan-binding lectin mediates renal ischemia/reperfusion injury independent of complement activation. Am J Transplant (2012) 0.96
In vivo biodistribution and lifetime analysis of cy5.5-conjugated rituximab in mice bearing lymphoid tumor xenograft using time-domain near-infrared optical imaging. Mol Imaging (2009) 0.94
Construction of miniantibodies for the in vivo study of human autoimmune diseases in animal models. BMC Biotechnol (2007) 0.92
Simple scale-up of recombinant antibody production using an UCOE containing vector. N Biotechnol (2011) 0.92
Prevention of arthritis by locally synthesized recombinant antibody neutralizing complement component C5. PLoS One (2013) 0.90
Two novel probes reveal tubular and vascular Arg-Gly-Asp (RGD) binding sites in the ischemic rat kidney. Kidney Int (1997) 0.90
Radiolabeled Cyclic RGD Peptide Bioconjugates as Radiotracers Targeting Multiple Integrins. Bioconjug Chem (2015) 0.86
Antiangiogenics meet nanotechnology. Cancer Cell (2002) 0.85
APT070 (Mirococept), a membrane-localised complement inhibitor, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury. Br J Pharmacol (2005) 0.84
Pathophysiology of renal tubular obstruction: therapeutic role of synthetic RGD peptides in acute renal failure. Kidney Int (1995) 0.83
Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice. Leukemia (2014) 0.82
The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: in vitro and in vivo studies. Eur J Immunol (2002) 0.82
Donor Pretreatment With IL-1 Receptor Antagonist Attenuates Inflammation and Improves Functional Potency in Islets From Brain-Dead Nonhuman Primates. Cell Transplant (2014) 0.80
Distribution of alphavbeta3, alphavbeta5 integrins and the integrin associated protein--IAP (CD47) in human glomerular diseases. Cell Adhes Commun (2000) 0.79
Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies. Int J Nanomedicine (2015) 0.78
Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery. Blood (2015) 0.77
Cardiac and nephroprotective effects of angiotensin converting enzyme inhibitor treatment in the renal ablation model. J Hypertens Suppl (1993) 0.77
Graft-Versus-Host Disease Following Liver Transplantation: Development of a High-Incidence Rat Model and a Selective Prevention Method. Am J Transplant (2016) 0.77
Prevention of arthritis by locally synthesized recombinant antibody neutralizing complement component C5. PLoS One (2013) 0.90
Tissue transglutaminase (TG2) enables survival of human malignant pleural mesothelioma cells in hypoxia. Cell Death Dis (2017) 0.75
Invasive meningococcal disease in three siblings with hereditary deficiency of the 8(th) component of complement: evidence for the importance of an early diagnosis. Orphanet J Rare Dis (2016) 0.75
Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers. Arthritis Res Ther (2016) 0.75
Defining the Disease-Specific Antigenic Repertoire. Front Microbiol (2020) 0.75
Celiac anti-type 2 transglutaminase antibodies induce differential effects in fibroblasts from celiac disease patients and from healthy subjects. Amino Acids (2016) 0.75
Meniscal Ossicles as micro-CT Imaging Biomarker in a Rodent Model of Antigen-Induced Arthritis: a Synchrotron-Based X-ray Pilot Study. Sci Rep (2017) 0.75